Summary In Britain, the specialty of palliative medicine continues to develop, encouraging the referral of patients early in the palliative phase of their illness. This has led to an increased number of patients receiving palliative chemotherapy and hospice care concurrently, posing special problems to the professionals involved.
In this retrospective study, 52 patinets were identified who received chemotherapy and hospice care simultaneously. Case notes were reviewed to reveal problems arising from sharing the duty of care. The poor quality of communication between professionals, perhaps reflecting a limited understanding of the various roles in patient care, was found to cause significant difficulties. The duration and discontinuation of cytotoxic therapy seems to be a particularly difficult matter. Hospice admission often signalled the end of this treatment. In a third of the patients, no decision was taken to stop chemotherapy desipite the last dose being an average of just I week before death. The value of chemotherapy for patients who are too ill to return home is questioned. Seven patients were diagnosed as suffering from chemotherapy-induced sepsis and neutropenia either by hospice inpatient or home care teams, and were admitted to their acute centres accordingly. Most patients who died during the study period received terminal care in the hospice.
Suggestions are made on improving professional education and communication, including the use of a 'chemotherapy card '. In Britain, the specialty of palliative medicine continues to develop, as described by Hillier (1988) , encouraging the referral of patients in the palliative, rather than the terminal, phase of their illness. Cancer patients are therefore being seen by hospital-based, hospice and community palliative care services earlier in the course of the illness than previously. This trend, coupled with the increasing use of palliative, cytotoxic chemotherapy by cancer physicians and surgeons, noted by Kearsley (1986) , has led to an increase in the number of patients referred for hospice care who are concurrently receiving anti-cancer therapy.
Our unit began to experience difficulties in the management of such patients. The problems appeared to fall into three main categories: (i) Lack of detail of the patients' current medical history. ( ii) The limited education of hospice staff in cytotoxic chemotherapy. (iii) The management of changes to treatment philosophies, relating to the different toxicities being acceptable depending on the phase of a patient's illness; namely potentially curative, palliative and terminal, Ashby and Stoffell (1991) . However, the hospice mutlidisciplinary team, concentrating on holistic care, felt that it had much to offer in this area, West (1990 Boyd (1992) .
This study was conducted in order to determine the causes for the problems the hospice team were facing and to suggest some solutions. (range: 29-86 for either sex).
Methods
The types of diagnoses represented are illustrated in Table I . The source of referral for hospice care and the nature of the involvement initially requested is shown in Table II . Once the referral had been accepted, the package of care was decided between the hospice team and the patient and his carers, in conjunction with the primary care team and the hospital consultant where appropriate. Thus, a patient initially referred for home care may well have spent some time in the hospice or at day care, and vice-versa.
The main source of medical information for each patient was the referral form. However, 24 out of 52 patients had no mention of any chemotherapy on the form. Six of these had been referred for hospice care before chemotherapy was instituted and the medical information had not been updated. Hospital records or photocopied notes were available on hospice admission for 14 of the 52 patients, and susbequently for a further ten. No notes were obtained for 28 patients. Of 18 patients transferred directly from hospital to the hospice, only seven had an accompanying medical letter. A letter from the GP accompanied two out of 11 patients admitted at the GP's request. Discharge or clinic letters including updated information on treatment and progress were sent to the hospice for 13 of the 52 patients. On 25 occasions, patients visited the hospital outpatient departments from their hospice beds, with accompanying letters. Two replies were received the same day. Table III illustrates the range and frequency of side effects attributed to palliative chemotherapy recorded in the hospice case notes. For each patient, problems occurring at anytime during chemotherapy were recorded. The actual anticancer treatment prescribed was often not known, and this table simply illustrates the range of problems managed by the hospice team, without attempting to comment on the treatment related toxicities of individual chemotherapeutic regimes. Initial admission to the hospice from home was organised either by the hospice home care team (19 patients) or the GP (1 1 patients). Ten of these admissions were urgent. Direct transfer from hospital was arranged for 22 patients as their first hospice admission. Eighteen of these were admitted Communication with patients and carers Hospice staff were often asked to enter into difficult discussions with patients and their carers as to the value of continuing cytotoxic therapy, and education of staff in this area is being undertaken. The complexity of the doctor-patient relationship, particularly when discussing the relative merit of different treatment options has been highlighted by Sensky and Catalan (1992) . They comment that anxiety and depression can occur in up to 60% of patients with serious physical illness and may alter perceptions about their treatment. Intelligent discussion with patients during the course of this study was hampered by the lack of appropriate medical information. Although the hospital team may feel best placed to deal with these issues, the informal atmosphere of the hospice or a patients home may be more conducive to such discussions; moreover, a professional who is distanced from the actual prescribing of treatment may be seen as more approachable. Many patients have loyalties to the doctors they have known over a long period of time and may fear 'letting them down' by questioning the value of continued treatment. Similarly medical staff may avoid this subject in order to 'maintain hope'. Complex issues arising between family members regarding the place of continued chemotherapy were often confronted. Previous studies have shown that carers often see communication with professionals as inadequate and would value more information, Sykes et al. (1992) .
The decision to stop chemotherapy That 33% (17/52) of patients died on chemotherapy, the last dose being so close to death also needs addressing. Two of these patients specifically requested that their treatment be continued, but the other 15 had not expressed such a wish. The continued treatment of these 15 patients, in view of the necessary visits to hospital and blood tests, in addition to the side effects incurred, poses many questions. In particular, the lack of clear endpoints to some chemotherapy regimes, may exacerbate this problem, as highlighted by Rubens et al. (1992) these patients. Opportunities exist in higher specialist training for palliative medicine, to gain experience in medical and clinical oncology. Equally, there is an opportunity for oncology trainees to spend some time working in a hospice. This provides an opportunity to improve the understanding between specialties. Hospice nursing staff are more aware of the potential benefits of chemotherapy and the different responsibilities of looking after these patients. Certainly, during the period of this study, as palliative care services have become a more integrated part of patient care, the case of joint audit between the professionals concerned has become more apparent.
An oncology treatment card One way of improving communication between all teams prescribing chemotherapy, patients, primary health teams and hospices, would be to provide a patient held record of cancer treatment. Some centres currently use a chemotherapy record card for this purpose, similar to that in Figure 1 . The authors are designing a more comprehensive cancer treatment booklet, in conjunction with the local Department of Medical Oncology. This will include a basic record of radiotherapy given, in addition to chemotherapy and other medication. It is hoped that this will undergo a pilot study and, if successful, be put to routine use. The present study could then be repeated, to complete the audit cycle.
Conclusions
(1) The holistic, multidisciplinary approach of hospice care has much to offer patients receiving palliative chemotherapy in terms of communications/counselling, day care, home care, and admissions for symptom control, respite and terminal care. Early referral aids the continuity of care and enables the hospice team to use its expertise, in conjunction with that of the hospital consultant and GP, to the patients best advantage.
(2) Education in the hospice is being addressed for all staff. Oncological experience is usually included in higher specialist training for palliative medicine. However, the hospice team cannot function well in this area without accurate, contemporary medical information. Perhaps junior staff in oncology should work in a hospice for a time in order to understand these difficulties.
(3) The minimum useful information of drugs prescribed and the dates administered could be provided on a 'chemotherapy card' given to each patient. This already occurs in some centres and should be encouraged. It would provide a simple, efficient way of communicating basic information, both to the specialist palliative care services and to the patient's GP. Ideally the hospice team would also value information on the treatment plan, assessable disease, and protocols of current, common clinical trials, which could be provided in a more comprehensive oncology treatment booklet given to patients. (4) This study indicates that joint clinical audit, coupled with the further integration of services may help to optimise the future management of this challenging group of patients. The appointment of a consultant in palliative medicine and oncology in one local teaching hospital should go some way to achieving this.
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